Breaking News

Alexza Appoints Quality VP

April 17, 2014

Brown brings 20 years of industry experience

Winston R. Brown, Jr. has been appointed vice president of Quality at Alexza Pharmaceuticals, Inc. Mr. Brown will be responsible for Quality Assurance, Quality Control and Quality Systems. He has more than 20 years of experience in global quality, regulatory compliance and development operations working with biopharmaceutical, medical device, and nutritional companies. 
Mr. Brown joins the company from Alcon Research, a division of Novartis, where he served as global head of Quality R&D, Pharmaceuticals, Biologics, and Vision Care Devices. Mr. Brown previously served as executive director, Global Quality Compliance for Baxter Healthcare International from 2009 to 2011. Mr. Brown also held positions with Bausch & Lomb as director of Site Quality, Vision Care-Sterile Ophthalmic Solutions, and held multiple leadership positions in quality systems/compliance, regulatory affairs, and process validation with Holopack Pharmaceuticals, USA and J&J Consumer Pharmaceuticals.
"We are pleased to welcome Winston to our team," said Robert A. Lippe, executive vice president, Operations and chief operations officer at Alexza. "Winston brings extensive quality program expertise coupled with strong operational leadership experience to our company, at a time of exciting growth in both scale and scope.  We look forward to his contributions in support of our efforts with the global ADASUVE launch and in expanding our candidate pipeline."

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016